Lanean...
Rational study endpoints in anti-neoplastic agent regulatory approval trials in the gynecologic malignancies
A discussion of rational endpoints in clinical trials seeking regulatory approval for new anti-neoplastic agents involving the three major gynecologic malignancies, cancers of the ovary, cervix, and endometrial, is particularly interesting as (in the opinion of this commentator) the conclusion will...
Gorde:
| Argitaratua izan da: | Womens Health (Lond) |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
SAGE Publications
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5373277/ https://ncbi.nlm.nih.gov/pubmed/27638892 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1745505716655555 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|